SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-19-008194
Filing Date
2019-12-18
Accepted
2019-12-18 07:00:28
Documents
13
Period of Report
2019-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_121819.htm   iXBRL 8-K 23554
  Complete submission text file 0001171843-19-008194.txt   228130

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3095
3 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25969
4 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 35566
5 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 24600
8 EXTRACTED XBRL INSTANCE DOCUMENT f8k_121819_htm.xml XML 3064
Mailing Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Filer) CIK: 0001629137 (see all company filings)

IRS No.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37539 | Film No.: 191291250
SIC: 2834 Pharmaceutical Preparations